AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
出版年份 2018 全文链接
标题
AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
作者
关键词
Cancer, Metastasis, AKT/PKB, Head and neck squamous cell carcinoma, Phenotypic screening, Epithelial-mesenchymal transition, Adhesion, Migration, Invasion
出版物
BMC CANCER
Volume 18, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-03-05
DOI
10.1186/s12885-018-4169-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Method for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial Cells
- (2017) Haixia Gong et al. Scientific Reports
- AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins
- (2017) Marina Riggio et al. Scientific Reports
- AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation
- (2016) Chia-Wei Li et al. CANCER RESEARCH
- PI3K-AKT-mTOR pathway proteins are differently expressed in oral carcinogenesis
- (2016) Fabiana Martins et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- AKT-ions with a TWIST between EMT and MET
- (2016) Huifang Tang et al. Oncotarget
- Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma
- (2016) Yordan Benhamou et al. Oncotarget
- Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
- (2016) Sherri Z. Millis et al. JAMA Oncology
- Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation
- (2016) Jae Won Chang et al. Scientific Reports
- Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and more brain damage
- (2016) Laura Ochoa-Callejero et al. Scientific Reports
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
- (2015) Yasuhiro Oki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
- (2015) Ramesh K. Ramanathan et al. CANCER
- Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
- (2015) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
- (2015) S. Gupta et al. CLINICAL CANCER RESEARCH
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
- (2015) B. B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
- (2015) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
- (2015) Daniel R. Simpson et al. ORAL ONCOLOGY
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
- (2014) I Brana et al. BRITISH JOURNAL OF CANCER
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
- (2014) M. Y. Konopleva et al. CLINICAL CANCER RESEARCH
- Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
- (2014) L Molife et al. Journal of Hematology & Oncology
- Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection
- (2014) Hua Li et al. MOLECULAR CANCER RESEARCH
- A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study
- (2014) Maryam Fouladi et al. PEDIATRIC BLOOD & CANCER
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
- (2014) Filip Janku et al. Cell Reports
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
- (2013) Matthew G. Fury et al. CANCER
- A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer
- (2013) Matthew G. Fury et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Targeting FAK Radiosensitizes 3-Dimensional Grown Human HNSCC Cells Through Reduced Akt1 and MEK1/2 Signaling
- (2012) Stephanie Hehlgans et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
- (2011) Matthew G. Fury et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ptenb Mediates Gastrulation Cell Movements via Cdc42/AKT1 in Zebrafish
- (2011) Chen-Min Yeh et al. PLoS One
- Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression
- (2009) R. L. Dillon et al. CANCER RESEARCH
- Targeting the PI3K signaling pathway in cancer
- (2009) Kwok-Kin Wong et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- PDGF signalling controls the migration of mesoderm cells during chick gastrulation by regulating N-cadherin expression
- (2008) X. Yang et al. DEVELOPMENT
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started